Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). Following the successful completion of the single ascending dose study in July 2009, a multiple ascending dose study, in which FX125L was administered orally once-daily in healthy subjects, was conducted also in the United States... 
More...
More...